The King's Thrombosis Centre has an active research programme with successful collaborations with Obstetrics & Gynaecology, Liver and General Medicine.
This study investigating the prothrombotic state associated with hormone replacement therapy (HRT) demonstrated transdermal preparations did not impact on thrombin generation, compared to a control population. Oral HRT was associated with significantly increased thrombin generation parameters compared to both transdermal users and healthy controls, suggesting hypercoagulability.
The DVT outcomes study demonstrated hypercoagulability associated with African-Caribbean ethnicity in both healthy volunteers and DVT participants, supporting the higher incidence of VTE seen in this group compared to Caucasians.
Quality of life was found to be reduced at DVT diagnosis with attenuated improvement in quality of life scores in those who developed post-thrombotic syndrome. Novel early predictors of post-thrombotic syndrome were also identified.
• Prospective case-control study investigating the prothrombotic phenotype in the severely obese
• Global coagulation assays in liver disease
• Role, acceptability and effect of thromboprophylaxis following childbirth
• What impact does body weight have on response to rivaroxaban therapy?
• Do blood brain-barrier efflux proteins confer a protective property against intracranial haemorrhage in those patients prescribed the novel oral anticoagulants, dabigatran and rivaroxaban?
We recruit and care for patients participating in commercial clinical trials, such as HOKUSAI VTE, which compares a novel anticoagulant, edoxaban to current standard therapy for proximal DVT and PE.